Aim of the study was to find and adaptate effective protocols for patients with relapsed, advanced, poor prognosis testicular cancer previously treated with cisplatincontaining (PEB, PVB, AVP) chemotherapy. Material and methods: Fourty four patients with germ cell tumours were treated according to the VIP protocol from October, 1989, to March 1993. We have evaluated the overall therapeutic effect and the side effects of the treatment in 39 patients. VIP shedule was as follows: Vepeside (Etoposide, VP-16) 100mglm2iv, infusion d1-5., Ifosfamide (Holoxan) 40mglkgiv. infusion dl-5., Cisplatin 20mg/mJ, dl-5. Uromitexan rescue was administered with the amount of 20% of the Ifosfamide dose before the Ifosfamide infusion, and following on the 4th and 8th hour. The patients have got proper hydration by additional infusions, and we held the urinary pH above 7. Results: In the 39 evaluable patients the following results had been achieved: CR: 4 (10,2%) PR: 10(25,6%), the remission rate was 35,9%. The best results were seen in patients with mixed histology, and stage Ill/B disease. Our results were better when tee used the VIP therapy as second line treatment (RR: 45,5%), than as third line (23,4%), but we did not observed significant differences in CR (9,1 vs, 11,7% respectively). The toxicity was acceptable. Discussion: VIP protocol with conventional doses of agents could be an effective treatment choice following cisplatin-based protocoh (PEB, PVB, AVP) in patients with developed resistency or relapsed disease. From the point of the response rate, VIP therapy is more effective as second line, than as third line treatment, hut there is not significant difference between CR s. Following previous cisplatin-containing protocols, it must be a careful follow-up of the patiens preventing renal toxicity what can be observed with greater incidence.
|Number of pages||4|
|Publication status||Published - dec. 1 1997|
ASJC Scopus subject areas